网站维护
系统内容更新/升级中
2021-4-13
In an effort to further grow the flow of innovation centered in the Basel Area, WuXi AppTec and BaseLaunch have joined forces to help young biopharmaceutical enterprises overcome some of the toughest hurdles in bringing novel therapeutics to market.
BaseLaunch is a significant enabler in one of the largest biopharmaceutical hubs of the European continent. As an actor in the highly interconnected ecosystem of international pharmaceutical giants, world-renowned academic institutions, and visionary investors of the Basel Area and beyond, BaseLaunch partners with scientists and entrepreneurs to help launch and grow exceptional biotech companies. Since 2018, they have supported 13 startups from incubation through series A financing (over USD 200M so far raised) and closing acquisition partnerships.
BaseLaunch is uniquely positioned to offer young and bold endeavors the key building blocks to drive their success. Support is highly customized, providing whatever is needed to help the ventures succeed through a network of connections, consultants, and partners who eliminate some of the largest hurdles in the path from idea to commercialization. WuXi AppTec has recently joined that network as a Domain Partner.
“For over 20 years, we have been working with partners across sector lines to strengthen the biopharmaceutical industry. From virtual companies to self-made startups and university spinoffs, we understand sector-specific challenges and have collaborated on solutions at every stage of the therapeutic development pipeline. Our objective is to enable any player looking to make a difference in healthcare to advance towards their goal,” explains Dave Madge, Vice President of WuXi AppTec Research Services Division. “We are excited to bring that expertise into the infrastructure that BaseLaunch has built and nourished. We see this partnership as a cornerstone of our global initiative to foster advances in healthcare by ensuring that good ideas and agile young companies can find and leverage opportunities.”
WuXi AppTec operates an open-access platform for services in Research & Development and manufacturing under a vision that “every drug can be made and every disease can be treated.” Several projects they support are collaborations to discover, develop, optimize, and advance future therapeutics based on novel concepts emerging from academic or basic research. WuXi AppTec has decades of experience developing small molecule drugs, cell and gene therapies, as well as testing medical devices.
As a Domain Partner, WuXi AppTec supports up-and-coming enterprises in the BaseLaunch portfolio in the discovery and development of future therapeutics. WuXi AppTec leverages comprehensive discovery and technology platforms to evaluate any drug modality, from small molecules and antibodies, to bi-functional molecules (PROTACs) and cell and gene therapies. With peer-recognized scientific leadership and expertise in oncology, immunology, infectious diseases, neurosciences, fibrosis, cardiovascular and metabolic disease, WuXi AppTec works collaboratively to rapidly advance programs from target through to preclinical selection and beyond. Startups can engage with WuXi AppTec scientists and technicians to plan, conduct, and evaluate studies in:
• In vivo and in vitro Pharmacology
• ADME/ DMPK
• Toxicology
Stephan Emmerth, Director BaseLaunch explains: “For many of our early-stage partners, shortening the roadmap to market means putting them in touch with our Domain Partners who can help them streamline processes and achieve milestones faster. Examining and profiling the behavior of candidate therapeutic agents within biological systems is an obligatory goal line for anyone bringing a pharmaceutical to market. Reaching that goal can be a complex process, fraught with pitfalls and setbacks. We believe that working with a world-class partner like WuXi AppTec helps young companies anticipate and mitigate risks. WuXi AppTec has deep knowledge of available technologies and assays so they can assist with developing experimental strategies and troubleshooting. They are familiar with best practices, can head off complications, and provide solutions to move projects forward. Finally, they own state-of-the-art facilities that allows drug discovery projects to commence as early as possible.”
With this partnership, WuXi AppTec becomes an active member of a dynamic community of innovation in the center of Europe. The Basel region is well-known as a biopharmaceutical hotspot, where a thriving cohort of small to medium-sized companies successfully emerge in a landscape of cutting-edge research institutions and technology parks. At the same time, WuXi AppTec enriches that community with its global reach and enabling infrastructure that can magnify the impact of new companies on global healthcare today and tomorrow. “Now more than ever, we have the opportunity to better meet the individual needs of patients with knowledge, expertise, and collaboration,” says Dave Madge. “This partnership is an important step to further enable healthcare innovation and realize our vision that ‘every drug can be made and every disease can be treated.’”
Read more about the partnership here: https://baselaunch.ch/
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,200 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."
Read more on www.wuxiapptec.com
About BaseLaunch
BaseLaunch is the Basel Area-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. BaseLaunch serves as a growth platform for early stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of business development. Operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area, BaseLaunch partners with leading global pharma companies and venture funds - those announced to date being Roche, Johnson & Johnson Innovation, BB Pureos Bioventures, Roivant Sciences, Bridgebio Therapeutics and CSL Behring - which also feed into the pool out of which BaseLaunch funds ventures. Regional and domain partners include the cantons of Basel-Landschaft, Basel-Stadt and Jura as well as Alloy Therapeutics, KPMG, SpiroChem, Vossius & Partner, Walder Wyss and WuXi AppTec. Since 2018, BaseLaunch supported ventures have raised over USD 200 million. Harnessing Basel Area’s unique position as a global life sciences hub, as well as its rising popularity among investors, BaseLaunch is looking to attract the next generation of breakthrough companies. Interested groups can find more information at www.baselaunch.ch
About Basel Area Business & Innovation
Basel Area Business & Innovation is the investment and innovation promotion agency dedicated to helping companies, institutions and startups find business success in the Basel Area. The organization targets and attracts companies to settle, supports founders of innovative ventures, and drives high growth initiatives in order to establish the region as the Swiss business and innovation hub of the future. The non-profit agency focuses on growing the area’s cutting-edge industries life sciences, healthcare and production technologies and manages the Switzerland Innovation Park Basel Area which houses the organization’s accelerator programs. The agency serves the cantons of Basel-Landschaft, Basel-Stadt and Jura. www.baselarea.swiss